A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations

ZhuGuangYing6 sites in 1 country30 target enrollmentJuly 2011

ConditionsNon-small Cell Lung Cancer

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Non-small Cell Lung Cancer
Sponsor: ZhuGuangYing
Enrollment: 30
Locations: 6
Primary Endpoint: Response rate (RR)
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.

Detailed Description

Worldwide more than half a million new cases of lung cancer are diagnosed annually. About 80% of these tumours are of non-small cell histological type. Surgery is the treatment of choice, but only about 20% of tumours are suitable for potentially curative resection. Concurrent chemoradiotherapy is the standard treatment for locally advanced NSCLC. When Iressa was used in the first-line treatment of advanced NSCLC with EGFR mutations positive, the 12-month rates of progression-free survival were 24.9%. Therefore, we speculate that the EGFR mutations in patients with locally advanced NSCLC, Gefitinib combined with radiotherapy may be better than chemoradiotherapy. We design the study to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.

Registry

clinicaltrials.gov

Start Date

July 2011

End Date

July 2017

Last Updated

14 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

ZhuGuangYing

Eligibility Criteria

Inclusion Criteria

•Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for surgery) or stage Ⅳ(only single-site single transfer );
•Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;
•Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);
•Patients must be informed of the investigational nature of the study and must sign an informed consent form;
•Presence of at least one measurable/evaluable according to RECIST criteria.
•ECOG performance Status 0-2 ;
•Patients must have a life expectancy \> 12 weeks;
•Patients with laboratory values as follows:WBC\>4.0 x 109/L; ANC≥1.5 x 109/L; PLT≥100 x 109/L; HGB≥10 g/dL; CR≤1.5 x ULN; TBIL\<1.5 x ULN; AST and ALT≤1.5 x ULN; LDH≤1.5 x ULN; AKP≤5 x ULN;
•FEV 1≥1.0L and \>50% Corresponding normal values;
•Patient candidate to standard platinum-based chemotherapy;

Exclusion Criteria

•Any evidence of clinically active interstitial lung disease;
•Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uterine and squamous cell carcinoma of the skin；
•Pregnancy or lactating；
•Serious concomitant infection;
•MI within preceding 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia;
•As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease);
•Patients who are not suitable to participate in the trial according to researchers.